aromasil has been researched along with Carcinoma, Lobular in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Barba, M; Barchiesi, G; Krasniqi, E; Mazzotta, M; Pizzuti, L; Vici, P; Villa, A | 1 |
| Chen, BE; Goss, PE; Liedke, PER; O'Shaughnessy, J; Parulekar, WR; Ramjeesingh, R; Shepherd, LE; Strasser-Weippl, K; Sudan, G | 1 |
| Bachelot, T; Racadot, S; Visy, A | 1 |
| Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Charehbili, A; Fontein, DB; Kranenbarg, EM; Kroep, JR; Linn, SC; Nortier, JW; Putter, H; van de Velde, CJ | 1 |
| Bertelli, G; Bliss, JM; Coombes, RC; Drosik, K; Hall, E; Ireland, E; Jassem, J; Karnicka-Mlodkowska, H; Snowdon, CF | 1 |
| Brueggemeier, RW; Layman, RM; Lehman, AM; Lustberg, MB; Mrozek, E; Povoski, SP; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shiels, DR; Sugimoto, Y; Zhao, W; Ziegler, RM | 1 |
| Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K | 1 |
| Bartlett, JM; Dirix, LY; Fontein, DB; Hille, ET; Kranenbarg, EM; Liefers, GJ; Nortier, JW; Paridaens, R; Putter, H; Robson, T; Roumen, RM; Seynaeve, C; van de Velde, CJ; van de Water, W; van Nes, JG | 1 |
| Belli, AK; Buckley, JM; Coopey, SB; Gadd, MA; Garber, JE; Guidi, AJ; Hughes, KS; Kim, EM; Mazzola, E; Parmigiani, G; Polubriaginof, F; Roche, CA; Sharko, J; Smith, BL; Specht, MC | 1 |
| Bafaloukos, D; Chrissochou, M; Gogas, H; Markopoulos, C; Michailidou, A; Misitzis, J; Papadiamantis, J; Tzoracoleftherakis, E; Xepapadakis, G; Zobolas, V | 1 |
| Vogel, V | 1 |
| Come, SE | 1 |
| Burns, R; Come, SE; Farag, N | 1 |
| Chessa, F; Farris, A; Madeddu, G; Manca, A; Pittalis, M; Sanna, D; Spanu, A | 1 |
1 review(s) available for aromasil and Carcinoma, Lobular
| Article | Year |
|---|---|
Chemoprevention in breast cancer.
Topics: Age Factors; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular; Female; Humans; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen | 2005 |
6 trial(s) available for aromasil and Carcinoma, Lobular
| Article | Year |
|---|---|
Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Treatment Outcome; Triazoles | 2018 |
Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).
Topics: Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Arthralgia; Arthritis; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Female; Hot Flashes; Humans; Joint Diseases; Logistic Models; Magnetic Resonance Imaging; Mammography; Mastectomy; Middle Aged; Multivariate Analysis; Musculoskeletal Diseases; Myalgia; Neoadjuvant Therapy; Odds Ratio; Osteoporosis; Postmenopause; Prognosis; Receptors, Estrogen; Treatment Outcome; Ultrasonography, Mammary; Vasomotor System | 2017 |
Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Double-Blind Method; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; International Agencies; Middle Aged; Postmenopause; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Ultrasonography | 2010 |
Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Pyrazoles; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sulfonamides; Survival Rate; Treatment Outcome | 2011 |
Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Humans; Postmenopause; Receptors, Estrogen; Tamoxifen | 2013 |
Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cholesterol; Enzyme Inhibitors; Female; Humans; Lipids; Middle Aged; Postmenopause; Risk Factors | 2005 |
9 other study(ies) available for aromasil and Carcinoma, Lobular
| Article | Year |
|---|---|
Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Everolimus; Female; Humans; Liver Neoplasms; Middle Aged; Premenopause; Progression-Free Survival | 2020 |
Radiation recall syndrome in a patient with breast cancer, after introduction of everolimus.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Estrogens; Everolimus; Female; Humans; Lymphatic Irradiation; Lymphocele; Mastectomy; Middle Aged; Neoplasms, Hormone-Dependent; Progesterone; Radiodermatitis; Radiotherapy, Intensity-Modulated; TOR Serine-Threonine Kinases | 2019 |
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Triazoles | 2014 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoprevention; Female; Humans; Hyperplasia; Mammary Glands, Human; Middle Aged; Precancerous Conditions; Raloxifene Hydrochloride; Tamoxifen | 2012 |
A 62-year-old woman with a new diagnosis of breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, Adjuvant; Combined Modality Therapy; Decision Making; Female; Humans; Mastectomy, Segmental; Middle Aged; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
Update: a 62-year-old woman with a new diagnosis of breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Tamoxifen | 2008 |
Planar scintimammography and SPECT in neoadjuvant chemo or hormonotherapy response evaluation in locally advanced primary breast cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Lymph Nodes; Mammography; Mass Screening; Middle Aged; Neoadjuvant Therapy; Organophosphorus Compounds; Organotechnetium Compounds; Prognosis; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 2008 |